Posts

Featured post

"Shotgun approach" to functional claiming fatal to RNA editing claims in Australia

The Australian Patent Office (APO) has issued a decision finding that ProQR Therapeutics II B.V.'s RNA editing antisense oligonucleotide claims are invalid for lack of sufficiency and support due to broad functional limitations and "unbridled" medical use claims in Wrays Solutions Pty Ltd v ProQR Therapeutics II B.V. [2026] APO 36 .   The decision demonstrates that the APO's approach to broad functional claiming is largely aligned with that in Europe and other major jurisdictions, while the approach to medical use claims reflects an arguably stricter standard that may require additional limitations to be sufficiently enabled. Brief background   The claims at issue relate to chemically modified antisense oligonucleotides ( AON s) that recruit a cell’s naturally occurring ADAR enzyme to achieve conversion of a target adenosine to inosine ( A-to-I editing ) in RNA by modifications in a "Central Triplet" of three sequential nucleotides. The claimed modifi...

[Guest post] Getty Images v Stability AI: the parties’ submissions and key points from the appeal

Trapped in the examples: Escaping intermediate generalisations in pharma patents

[Guest Post] Nepal’s Supreme Court bats for protection of “established” GIs

Never Too Late: If you missed the IPKat last week!

AI in the patent industry: Have you read the terms and conditions?

[Guest Book Review] Dr Baer’s Introduction to Intellectual Property